OS Therapies’ (OSTX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report sent to investors on Wednesday,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Separately, Maxim Group assumed coverage on shares of OS Therapies in a research report on Tuesday, November 26th. They set a “buy” rating and a $8.00 price target on the stock.

OS Therapies Trading Down 28.4 %

NYSE:OSTX opened at $2.95 on Wednesday. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00. The business’s 50 day moving average is $3.32.

Insider Buying and Selling at OS Therapies

In related news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total value of $112,692.80. Following the sale, the insider now owns 2,531,211 shares in the company, valued at approximately $17,060,362.14. This represents a 0.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.